Samjin Pharmaceuticals Co., Ltd. (005500.KS) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	311.4B	309.1B	308.3B	292.1B	274.0B
Cost of Revenue	169.3B	156.1B	179.4B	146.2B	156.3B
Gross Profit	142.1B	153.0B	129.0B	145.9B	117.7B
Operating Expenses
R&D Expense	22.2B	35.7B	4.5B	4.2B	3.7B
SG&A Expense	62.2B	41.9B	41.2B	41.5B	42.7B
General & Admin Expense	32.4B	16.7B	14.9B	15.1B	17.1B
Selling & Marketing Expense	11.0B	25.2B	26.3B	26.3B	25.6B
Other Expenses	45.9B	50.8B	51.6B	80.8B	48.2B
Total Operating Expenses	121.1B	128.3B	97.3B	126.4B	94.6B
Cost and Expenses	290.4B	284.5B	276.7B	271.6B	250.8B
Operating Income (EBIT)	21.0B	24.7B	31.6B	19.5B	23.2B
Non-Operating
Interest Income	388.9M	369.1M	192.3M	89.4M	153.5M
Interest Expense	4.7B	5.0B	4.9B	4.4B	1.8B
Net Interest Income	(4.3B)	(4.6B)	(4.7B)	(4.3B)	(1.6B)
Other Non-Op Income/Expense	1.6B	(2.6B)	12.0B	(4.9B)	2.0B
Non-Operating Income (excl Interest)	(3.3B)	—	(16.9B)	501.7M	(3.8B)
EBT (Pre-Tax Income)	23.7B	22.1B	43.6B	15.6B	25.2B
Income Tax Expense	467.1M	(2.1B)	4.4B	(3.3B)	3.3B
Bottom Line
Net Income	23.3B	24.2B	39.2B	18.9B	21.9B
Earnings from Cont. Ops	23.3B	24.2B	39.2B	18.9B	21.9B
Earnings from Discont. Ops	—	—	—	—	(1.2K)
Bottom Line Net Income	23.3B	24.2B	39.2B	18.9B	21.9B
Per Share
Basic EPS	₩1,869	₩1,963	₩3,111	₩1,460	₩1,728
Diluted EPS	₩1,869	₩1,963	₩3,111	₩1,460	₩1,728
Revenue Per Share	₩24,598	₩25,231	₩24,449	₩22,556	₩21,627
Shares
Basic Shares Outstanding	12.7M	12.3M	12.6M	13.0M	12.7M
Diluted Shares Outstanding	12.7M	12.3M	12.6M	13.0M	12.7M
Profitability Metrics
EBITDA	19.2B	44.5B	65.9B	36.6B	36.8B
D&A	21.2B	19.8B	17.4B	16.6B	9.8B
EBIT	(2.0B)	24.7B	48.5B	20.0B	27.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026